Lilly’s Cymbalta Nabs Ped Exclusivity, Purdue Studies OxyContin in Children
Eli Lilly’s antidepressant Cymbalta will remain patent protected until December 2013, now that the company has snagged an additional six months U.S. marketing exclusivity by conducting FDA-requested pediatric trials.
300 N. Washington St., Suite 200, Falls Church, VA 22046, USA.
Phone (703) 538-7600 - Fax (703) 538-7676 - Toll free (888) 838-5578.
Copyright by FDAnews. All rights reserved. Do not duplicate or redistribute in any form.